PCM
ARQT icon

Penserra Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Penserra Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-82,463
Closed -$2.39M – 1087
2025
Q4 		$2.39M Buy
+82,463
New +$2.11M 0.03% 326
2025
Q2 		– Sell
-118,521
Closed -$1.85M – 1027
2025
Q1 		$1.85M Buy
+118,521
New +$1.67M 0.03% 315
2021
Q4 		– Sell
-1,155
Closed -$27K – 1372
2021
Q3 		$27K Buy
1,155
+10
+0.9% +$228 ﹤0.01% 1201
2021
Q2 		$31K Buy
1,145
+15
+1% +$423 ﹤0.01% 1088
2021
Q1 		$32K Buy
1,130
+130
+13% +$4.06K ﹤0.01% 886
2020
Q4 		$28K Buy
+1,000
New +$24.5K ﹤0.01% 792

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Penserra Capital Management's ARQT Position: Q1 2026 in Review

Penserra Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 82,463 shares — an estimated $2.39M sold.

Penserra Capital Management first reported a position in ARQT in Q4 2020 and held it in 6 quarters. The position peaked at $2.39M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Penserra Capital Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 82,463 Arcutis Biotherapeutics shares in Q1 2026, an estimated $2.39M.
  • Penserra Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 6 quarters.
  • Penserra Capital Management's Arcutis Biotherapeutics position peaked at $2.39M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.